R1DY34 Stock Overview
Operates as an integrated pharmaceutical company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Dr. Reddy's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹14.78 |
| 52 Week High | ₹16.34 |
| 52 Week Low | ₹11.22 |
| Beta | 0.36 |
| 1 Month Change | 4.08% |
| 3 Month Change | -2.44% |
| 1 Year Change | 37.23% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 61.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| R1DY34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 7.6% | -3.4% | -2.1% |
| 1Y | 37.2% | -27.4% | -11.7% |
Return vs Industry: R1DY34 exceeded the BR Pharmaceuticals industry which returned -27.4% over the past year.
Return vs Market: R1DY34 exceeded the BR Market which returned -11.7% over the past year.
Price Volatility
| R1DY34 volatility | |
|---|---|
| R1DY34 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in BR Market | 9.5% |
| 10% least volatile stocks in BR Market | 2.8% |
Stable Share Price: R1DY34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine R1DY34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 27,048 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Dr. Reddy's Laboratories Limited Fundamentals Summary
| R1DY34 fundamental statistics | |
|---|---|
| Market cap | R$80.09b |
| Earnings (TTM) | R$3.82b |
| Revenue (TTM) | R$21.48b |
21.0x
P/E Ratio3.7x
P/S RatioIs R1DY34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R1DY34 income statement (TTM) | |
|---|---|
| Revenue | ₹299.87b |
| Cost of Revenue | ₹122.07b |
| Gross Profit | ₹177.80b |
| Other Expenses | ₹124.47b |
| Earnings | ₹53.33b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 64.02 |
| Gross Margin | 59.29% |
| Net Profit Margin | 17.79% |
| Debt/Equity Ratio | 14.2% |
How did R1DY34 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:46 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Reddy's Laboratories Limited is covered by 77 analysts. 38 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |